News

Patients with mild Alzheimer’s disease who were given the 800mg twice-daily dose of Flurizan demonstrated a 44% slowing of decline in their performance of activities of daily living,

Under the agreement, Genmab has granted Serono exclusive worldwide rights to develop and commercialize Genmab’s HuMax-TAC. Genmab will receive an upfront payment of $2 million and is entitled

GSK will pay $4.40 in cash for each share of Corixa common stock, or common stock equivalent, or approximately $300 million. Selected Corixa board members and their investment

Byetta (exenatide) injection is the first in a new class of medicines known as incretin mimetics and will be used to treat patients who have not achieved adequate

Exelixis believes that XL844 is the first potent, selective inhibitor of the checkpoint kinase pathway to progress to this stage of development. In addition to its therapeutic potential

The trial evaluated the performance of talabostat in combination with docetaxel in patients with stage IIIb/IV non-small cell lung cancer (NSCLC) who have not responded to platinum-based therapy.

Under the agreement, Avanir is eligible to receive over $200 million in upfront and milestone payments. Avanir is also eligible to receive increasing royalties on product sales in

The new license is in addition to an existing agreement between the companies that grants Genentech exclusive rights to use ImmunoGen’s technology with therapeutic antibodies to HER2. ImmunoGen’s

Using the company’s proprietary biochronomer bioerodible drug delivery system with granisetron, APF530 is designed to provide therapeutic levels of the drug in order to give four to five